Galderma’s Mirvaso Joins Rosacea Market With Indication For Facial Erythema
This article was originally published in The Pink Sheet Daily
Executive Summary
The dermatology company is able to offer a continuum of care for patients with the skin condition now that it has received FDA approval for a third product to treat the condition. The latest offering treats the most mild form of the condition.